In short: BUY. ER 11.73%; fwd PE 10.9 vs 14.2 (23.2% under); RDCF 2.4% vs 6.0%. YTD +26.1%.
In short: BUY. An Italian luxury-yacht builder. ER 11.63% on 6.0% growth and a 2.6% yield; fwd PE 10.9 against a 14.2 average (23.2% under); RDCF 2.9% required vs 6.0% expected. Fair value €44.5 vs €38.90 — only 12.5% under. YTD +28.2%.
In short: BUY, up 18.0% YTD. FV €42.0 vs €35.8 = 14.8% under; ER 11.7%; fwd PE 10.9 against 14.2 (23.2% under); RDCF −1.9% required vs 6.0% expected — the price implies decline at a yacht maker compounding at 13.0% over ten years.
In short: BUY, and the tenth-best performer of the year (+25.7%). FV €44 vs €38.2 = 13.3% under; ER 11.7%; fwd PE 10.9 against 14.2 (23.2% under); RDCF −1.3% required vs 6.0% expected — the price implies decline in a luxury-yacht maker compounding at 14.3% over ten years.
In short: BUY, and the marginal name on the list — the 49th and last, right at the 10% expected-return cutoff. EPS growth 3.8%, dividend 3.2%, FWD PE 10.9 against a fair exit 14.2, expected return 10.0%, fair value 33.3 against 33.2 = 0.2% undervalued.
In short: BUY. 21.7x forward against a 14.2x five-year average — the sheet lists it as 26.4% under despite the multiple sitting above its own history, one of several rows where the published columns do not reconcile. Expected return 13.7% on a 3.3% yield and only 3.8% growth; reverse-DCF margin +5.1pp. Down 15.6% year to date.
In short: BUY, and ninth on the reverse-DCF screen. 10.2x forward — the second-lowest on the Buy list — against a 14.2x average (28.2% under), a 13.2% expected return built on a 3.3% dividend yield, and a reverse DCF implying negative 3.5% growth against 6.0% expected (a +9.5pp margin). A €40.4 fair value against €31.05.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.